Literature DB >> 10537119

Targeted overexpression of galanin in lactotrophs of transgenic mice induces hyperprolactinemia and pituitary hyperplasia.

A Cai1, J D Hayes, N Patel, J F Hyde.   

Abstract

We generated transgenic mice that carry 4.6 kb of the mouse galanin gene fused to 2.5 kb of the rat PRL promoter. In all transgenic lines that carried and transmitted the transgene, there were significant increases in galanin messenger RNA and peptide levels in the anterior pituitary in both male and female transgenic mice, and the elevation of galanin was restricted to the anterior lobe. Furthermore, galanin release from pituitary cells in vitro of both male and female transgenic mice was dramatically increased compared with that in control mice. At 2-4 months of age, pituitary PRL contents in female transgenic mice were increased compared with those in normal controls. Moreover, PRL messenger RNA levels were increased in female transgenic mice. However, plasma levels of PRL in female transgenic mice were not significantly higher until 6 months of age. By 11 months of age, cell numbers in the anterior pituitary were increased in female, but not male, transgenic mice. The percentage of lactotrophs in female transgenic mice as well as PRL gene expression per cell were significantly higher. No differences were detected in PRL content, gene expression, or release between normal and transgenic male mice. Six weeks of estrogen treatment significantly increased anterior pituitary weights and PRL secretion in male transgenic mice compared with that in normal male mice. In addition, anterior pituitary weights and PRL secretion were decreased in female transgenic mice compared with controls 6 weeks after ovariectomy. We conclude that overexpression of galanin in lactotrophs stimulates PRL synthesis and secretion and acts as a growth factor resulting in the formation of pituitary hyperplasia and hyperprolactinemia. Furthermore, estrogen appears critical for these galanin-mediated events.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10537119     DOI: 10.1210/endo.140.11.7120

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  6 in total

Review 1.  Paracrinicity: the story of 30 years of cellular pituitary crosstalk.

Authors:  C Denef
Journal:  J Neuroendocrinol       Date:  2008-01       Impact factor: 3.627

Review 2.  Galanin and its receptors in neurological disorders.

Authors:  Linda Lundström; Anna Elmquist; Tamas Bartfai; Ulo Langel
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

3.  Co-aggregation and secondary nucleation in the life cycle of human prolactin/galanin functional amyloids.

Authors:  Debdeep Chatterjee; Reeba S Jacob; Soumik Ray; Ambuja Navalkar; Namrata Singh; Shinjinee Sengupta; Laxmikant Gadhe; Pradeep Kadu; Debalina Datta; Ajoy Paul; Sakunthala Arunima; Surabhi Mehra; Chinmai Pindi; Santosh Kumar; Praful Singru; Sanjib Senapati; Samir K Maji
Journal:  Elife       Date:  2022-03-08       Impact factor: 8.713

4.  Rat strain specific attenuation of estrogen action in the anterior pituitary gland by dietary energy restriction.

Authors:  Djuana M E Harvell; Linda K Buckles; Karen A Gould; Karen L Pennington; Rodney D McComb; James D Shull
Journal:  Endocrine       Date:  2003-07       Impact factor: 3.633

Review 5.  Potential of gene therapy for the treatment of pituitary tumors.

Authors:  R G Goya; D K Sarkar; O A Brown; C B Hereñú
Journal:  Curr Gene Ther       Date:  2004-03       Impact factor: 4.391

Review 6.  The Galaninergic System: A Target for Cancer Treatment.

Authors:  Manuel Lisardo Sánchez; Rafael Coveñas
Journal:  Cancers (Basel)       Date:  2022-08-01       Impact factor: 6.575

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.